Neuron 80, 613623
Off-Label Use Identification : Utilizes member medical claims history to identify use of T2D therapies without a confirmed diagnosis
Chang, Y., Hsieh, M.-H., Ju, P.-C
Dosing Strategies for Weight Loss Weight Loss Results with Retatrutide Phase 2 trial results by dose: 1mg produced 8.7% weight loss, 4mg hit 17.3%, 8mg reached 22.8%, and the 12mg group lost 24.2% at 48 weeks
To help provide insights into the potential role of oral semaglutide in current T2D management, this article aims to discuss the pharmacology of oral semaglutide, review the current clinical evidence on the efficacy and safety of this agent from the extensive phase III PIONEER clinical trial program in patients with T2D, and describe findings from initial cost-effectiveness studies
Consistently challenging your muscles is the key to seeing optimal results